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BACKGROUND: Ex vivo uterine environment therapy is an experimental day gestation and were killed at 100-day gestation to allow comparative
intensive care strategy for extremely preterm infants born between21and 24
weeks of gestation. Gas exchange is performed bymembranous oxygenators
connected by catheters to the umbilical vessels. The fetus is submerged in a
bath of synthetic amniotic fluid. The lungs remain fluid filled, and pulmonary
respiration does not occur. Intrauterine inflammation is strongly associated
with extremely preterm birth and fetal injury. At present, there are no data
that we are aware of to show that artificial placentaebased systems can be
used to support extremely preterm fetuses compromised by exposure to
intrauterine inflammation.
OBJECTIVE: To evaluate the ability of our ex vivo uterine environment
therapy platform to support extremely preterm ovine fetuses (95-day
gestational age; approximately equivalent to 24 weeks of human gesta-
tion) exposed to intrauterine inflammation for a period of 120 hours, the
following primary endpoints were chosen: (1) maintenance of key physi-
ological variables within normal ranges, (2) absence of infection and
inflammation, (3) absence of brain injury, and (4) gross fetal growth and
cardiovascular function matching that of age-matched in utero controls.
STUDY DESIGN: Ten ewes with singleton pregnancies were each
given a single intraamniotic injection of 10-mg Escherichia coli lipopoly-
saccharides under ultrasound guidance 48 hours before undergoing
surgical delivery for adaptation to ex vivo uterine environment therapy at
95-day gestation (term¼150 days). Fetuses were adapted to ex vivo
uterine environment therapy and maintained for 120 hours with constant
monitoring of key vital parameters (ex vivo uterine environment group)
before being killed at 100-day equivalent gestational age. Umbilical artery
blood samples were regularly collected to assess blood gas data, differ-
ential counts, biochemical parameters, inflammatory markers, and mi-
crobial load to exclude infection. Ultrasound was conducted at 48 hours
after intraamniotic lipopolysaccharides (before surgery) to confirm fetal
viability and at the conclusion of the experiments (before euthanasia) to
evaluate cardiac function. Brain injury was evaluated by gross anatomic
and histopathologic investigations. Eight singleton pregnant control ani-
mals were similarly exposed to intraamniotic lipopolysaccharides at 93-Cite this article as: Usuda H, Watanabe S, Saito M, et al.
Successful use of an artificial placentaebased life sup-
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https://doi.org/10.1016/j.ajog.2020.04.036postmortem analyses (control group). Biobanked samples from age-
matched saline-treated animals served as an additional comparison
group. Successful instillation of lipopolysaccharides into the amniotic fluid
exposure was confirmed by amniotic fluid analysis at the time of admin-
istration and by analyzing cytokine levels in fetal plasma and amniotic fluid.
Data were tested for mean differences using analysis of variance.
RESULTS: Six of 8 lipopolysaccharide control group (75%) and 8 of 10
ex vivo uterine environment group fetuses (80%) successfully completed their
protocols. Six of 8 ex vivo uterine environment group fetuses required dexa-
methasone phosphate treatment to manage profound refractory hypotension.
Weight and crown-rump length were reduced in ex vivo uterine environment
group fetuses at euthanasia than those in lipopolysaccharide control group
fetuses (P<.05). There were no biologically significant differences in cardiac
ultrasoundmeasurement, differential leukocyte counts (P>.05), plasma tumor
necrosis factor a, monocyte chemoattractant protein-1 concentrations
(P>.05), or liver function tests between groups. Daily blood cultures were
negative for aerobic and anaerobic growth in all ex vivo uterine environment
group animals. No cases of intraventricular hemorrhage were observed. White
matter injury was identified in 3 of 6 lipopolysaccharide control group fetuses
and 3 of 8 vivo uterine environment group fetuses.
CONCLUSION:We report the use of an artificial placentaebased system
to support extremely preterm lambs compromised by exposure to intra-
uterine inflammation. Our data highlight key challenges (refractory hypo-
tension, growth restriction, and white matter injury) to be overcome in the
development and use of artificial placenta technology for extremely preterm
infants. As such challenges seem largely absent from studies based on
healthy pregnancies, additional experiments of this nature using clinically
relevant model systems are essential for further development of this tech-
nology and its eventual clinical application.
Key words: artificial placenta, chorioamnionitis, extremely preterm in-
fants, ex vivo uterine environment therapy, fetal inflammatory response,
fetal brain injuryreterm birth (delivery before 37P weeks’ gestation) is a leading cause
of death among children younger than 5
years and of long-term disability.1
Globally, more than 1,000,000 prema-
ture babies die each year.2 Overall out-
comes for preterm infants have
markedly improved over the past 5 de-
cades as a result of advances in neonatalNOVEMBER 2020 Ameriand obstetrical care including antenatal
steroid therapy and postnatal adminis-
tration of exogenous surfactant.3
Infants born at the border of viability
(21e24 weeks’ gestation) continue to
have an extremely high risk of death or
severe complications.1 Outcomes for
extremely premature (<28 weeks’
gestation) and extremely lowcan Journal of Obstetrics & Gynecology 755.e1
AJOG at a Glance
Why was this study conducted?
To determine the ability of a refined artificial placentaebased life support plat-
form to maintain extremely preterm ovine fetuses exposed to intrauterine
inflammation, a common antecedent of extremely preterm birth.
Key findings
Our artificial placenta platform was successfully used to maintain 8 extremely
preterm fetuses for a predetermined period of 120 hours. Biological parameters
and cardiovascular performance were largely equivalent to in utero controls.
Infection or additional injury was not identified.
What does this add to what is known?
This study presents the first data, of which we are aware, demonstrating the ability
of an artificial placentaebased life support platform to support extremely preterm
ovine fetuses compromised by exposure to intrauterine inflammation. Intra-
uterine inflammation is a common antecedent of extremely preterm birth and is
associated with adverse outcomes. These data underscore the potential clinical
application and highlight the additional refinements required before an artificial
placentaebased system can be considered a viable treatment option for extremely
preterm infants born at the border of viability.
Original Research OBSTETRICS ajog.orgbirthweight infants (ELBW; <1000 g)
have improved little over the past 2
decades.1,4e6 One of the factors respon-
sible for this relative lack of improve-
ment in outcomes is that ventilation-
based life support systems may have
reached an efficacy threshold when used
to support the extremely underdevel-
oped cardiopulmonary system.6,7
We have developed an experimental
treatment platform for extremely preterm
infants, that is, ex vivo uterine environ-
ment (EVE) therapy.8e11 The central
principle underlying the iterative devel-
opment of this platform is to treat
extremely preterm infants as fetuses,
rather than as small babies, and in doing
so avoid the use of pulmonary gas ex-
change. Although longer survival with a
range of comparatively mature fetal
models has been repeatedly demonstrated
in sheep and goats over the past 30 years
(broadly corresponding to 28e32 weeks’
gestation in humans),9,12e15 the feasi-
bility of using an artificial placentaebased
system to successfully maintain extremely
preterm fetuses representative of the
developmental stage of extremely pre-
term human fetuses was only recently
demonstrated for the first time.8
One significant question that has not
been addressed over the 60-year history755.e2 American Journal of Obstetrics & Gynecolof artificial placenta development is
whether or not such a system could be
used to support compromised
fetuses.8e15 This is an extremely impor-
tant consideration given that intrauter-
ine infection and inflammation are
common antecedents of extremely pre-
term labor (PTL) and likely affect the
ability of a fetus to adapt to artificial
placentaebased treatments. It is re-
ported that 40%e70% of cases of PTL
are associated with chorioamnionitis,
with prevalence correlated to fetal
gestational age (GA) at preterm de-
livery.16,17 For example, chorioamnio-
nitis is observed in nearly 70% of
deliveries at 24 weeks’ gestation or
earlier, but in only 16% of cases delivered
at 34 weeks’ gestation.18
The presence of a fetal inflammatory
response is strongly associated with not
only PTLs but also a higher rate of fetal
complications and death.19,20 In partic-
ular, inflammation in response to mi-
croorganisms in the amniotic
environment is associated with life-
threatening lung injuries represented by
bronchopulmonary dysplasia21,22 and
neonatal brain injuries represented by
white matter injury (WMI) or hemor-
rhage, resulting in the subsequent diag-
nosis of cerebral palsy.23,24 We suggestogy NOVEMBER 2020that for artificial placentaebased sys-
tems to be used clinically, the technology
must be capable of supporting extremely
preterm fetuses compromised by expo-
sure to intrauterine inflammation.
We report the ability of our EVE
therapy platform to support extremely
preterm lambs (95-day GA; weighing
approximately 600 g; equivalent to
approximately 24 weeks’GA in humans)
after exposure to intrauterine inflam-
mation caused by intraamniotic (IA)
exposure to Escherichia coli lipopolysac-
charides (LPS)25,26 for a period of 120
hours. Although LPS elicits a sterile in-
flammatory response (as distinct from
the use of viable microorganism), its use
has the advantage of allowing the gen-
eration of a well-characterized and
strong intrauterine inflammatory
response, chorioamnionitis, and patho-
logic changes in a number of fetal sys-
tems including the lung and brain.
A 120-hour maintenance period was
chosen for this study based on clinical
data showing that the preponderance of
death and injury identified in extremely
preterm infants occurs acutely after de-
livery. In addition, in our experience,
adverse outcomes in the EVE therapy
model similarly occur within 2e3 days
of establishment of the life support
platform. The primary outcome mea-
sures were (1) maintenance of key
physiological parameters, (2) absence of
infection and inflammation, (3) absence
of brain injury, and (4) growth and car-
diovascular function patterns matching




All procedures and measurements were
performed in Perth, Western Australia,
after review and approval by the Animal
Ethics Committee of the University of
Western Australia (RA/3/100/1378).
This study consisted of 2 experimental
groups:
1. An IA LPS-exposed EVE therapy
group (EVE group) comprising fe-
tuses exposed to LPS for 2 days before
delivery and maintenance on EVE
therapy for 5 days (n¼10)
ajog.org OBSTETRICS Original Research2. An IA LPS control group (LPS con-
trol group) comprising fetuses
remaining in utero for 7 days after
LPS exposure (n¼8)
Additional tissues from age-matched,
saline-exposed animals were obtained
from our BioBank8,26 to establish a third
saline control group (3) to allow for an
LPS-naive comparison with LPS-
exposed tissues.
Study protocol
Ex vivo uterine environment
group
Ten Merino cross ewes (term: approxi-
mately 150 days) with timed, singleton
pregnancies were given single 10-mg IA
LPS injection under ultrasound guid-
ance at a GA of 92e93 days with suc-
cessful amniotic fluid (AF) placement
confirmed, as described previously.25,26
Fetuses were surgically delivered 48
hours later at 94- to 95-day GA and
adapted to EVE therapy as follows.
Surgical delivery. Ewes were fasted for
12 hours before surgery with ad libitum
access to water. Ewes were premedicated,
anesthetized, intubated, and ventilated
(acepromazine 0.03 mg/kg and bupre-
norphine 0.01 mg/kg intramuscularly,
midazolam 0.25 mg/kg and ketamine 5
mg/kg intravenously, 1%e2% isoflurane
in 100% oxygen inhaled, tidal volume 10
mL/kg 8e10 breaths/min) during the
surgical procedure. Intravenous fluids
(0.9% NaCl) were administered at a rate
of 10 mL/kg/h. The ewe’s abdomen was
clipped to expose the skin and thor-
oughly prepared for surgery, as
described previously.8e11,27 Ewes in both
the EVE and control groups were killed
with an intravenous bolus of pentobar-
bitone (160 mg/kg). After a maternal
laparotomy and hysterotomy, the fetuses
were placed inside the sterilized artificial
uterus, with care taken to ensure um-
bilical cord patency. Fetuses were inter-
mittently bathed with sterile saline
warmed to 40C. The catheterization
procedure was performed before de-
livery as follows:
1. In a procedure lasting approximately
10e15 min, 1 umbilical artery wascatheterized (8 Fr, Bio-Medicus 1-
piece femoral venous cannulae; Med-
tronic,Minneapolis,MN) and secured
approximately 7e8 cm outside the
umbilical ring. The tip of the arterial
catheter was sited approximately 2e3
cm from the umbilical ring.
2. One umbilical vein was then quickly
cannulated with an 8-Fr custom-
made catheter (Nipro Corporation,
Osaka, Japan) and secured approxi-
mately 1.5e2 cm external to the
umbilical ring. The tip of the venous
catheter was sited approximately
0.5e1 cm past the umbilical ring.
The fetuses were then attached to 1
membranous oxygenator.
3. A second umbilical artery was
catheterized while the circuit was
temporally circulated with 1 umbili-
cal artery and umbilical vein and then
connected to the circuit.
4. Finally, the fetus was carefully trans-
ferred to the site to be maintained,
and the bag was promptly filled with
synthetic AF.
Maintenance after delivery
EVE group fetuses were maintained and
observed in parallel by a single investi-
gator on a rotating 24-hour shift; 24
hours after commencement of the EVE
therapy, normal intermittent active fetal
swallowing movements, breathing
movements, gross fetal body move-
ments, and flexure and extension of
limbs were assessed at least every 6
hours. The presence of edema, ascites,
pleural effusions, or bleeding was
determined by ultrasound (single oper-
ator) and by gross examination during
necropsy after 120 hours of EVE therapy.
Fetuses were continuously treated
with intravenous heparin (12.5 U/kg/h)
to prevent blood coagulation, with the
dose adjusted after stabilization in an
attempt to maintain an activated clotting
time of 180e250 seconds. Prostaglandin
E1 (PGE1) (40 ng/kg/min, Tandetron;
Takata Pharmaceutical, Saitama, Japan)
was continuously administered after
delivery. Phosphodiesterase type 3 in-
hibitor (0.5 mg/kg/min, Primacor;
Sanofi, Sydney, Australia) was given to
assist maintenance of organ blood
flow.28 Midazolam was continuouslyNOVEMBER 2020 Ameriadministered for the first 6 hours (0.15
mg/kg/h).8 Hypoxia is characteristic for
fetuses exposed to chorioamnionitis and
a significant factor for severe brain
injury. Oxygen supply to the membra-
nous oxygenators was strictly adjusted to
maintain fetal PaO2 within a normal
range between 15 and 30 mm Hg.29e31
The fetuses were maintained with EVE
therapy for 120 hours, followed by
euthanasia with intravenous pentobar-
bitone (160 mg/kg/dose) for measure-
ments of body weight (BW), crown-




We defined refractory hypotension as
hypotension resulting in a decrease of
circuit flow below 150 mL/kg/min
(normal circuit flow is 150e250 mL/kg/
min),32e34 which required glucocorti-
coid administration in addition to vol-
ume expansion (10e20 mL/kg/h) with
fresh-frozen plasma (FFP) to be
resolved. To prevent critical refractory
hypotension (which is frequently
observed in extremely preterm infants at
the border of viability), intravenous hy-
drocortisone (HC) (3 mg) was admin-
istered to all fetuses immediately after
EVE therapy induction, followed by 6-
hourly administrations at a dose of 3
mg (estimated 3e4 mg/kg, approxi-
mately 60 hours) and 2 mg (estimated
2e3 mg/kg, approximately 120 hours).8
If refractory hypotension could not be
controlled after primary administration
of HC, a second dose of HC (3 mg) and
increased volume expansion (30 mL/kg/
h) and finally intravenous dexametha-
sone (Dex; 0.15mg/dose, estimated 0.25
mg/kg/dose; Hospira Australia, Mel-
bourne, Australia) was provided. Hypo-
tension and circuit flow were evaluated
every 5e10 min after HC or Dex injec-
tion. Iterative Dex was provided until
hypotension and circuit flow were
managed within normal range. FFP was
provided for volume expansion accord-
ing to hypotension for the first 4e6
hours (10e30 mL/kg/h) to all fetuses.8
Inotropic drug use was avoided to pre-
vent contraction of the umbilical
arteries.can Journal of Obstetrics & Gynecology 755.e3
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Intravenous nutrition comprised
glucose (9.5%e10%), amino acids
(3e3.2 g/kg/d, Pleamin-P injection;
Fuso Pharmaceutical, Osaka, Japan),
lipid (0.1 g/kg/d, Intralipid 20%; Frese-
nius Kabi Australia, Sydney, Australia),
vitamin compounds (1/8 vial/d, Dai-
medin multi injection; Nichi-Iko Phar-
maceutical, Tokyo, Japan),
micronutrient (0.1 mL/d, Cizanarine N
injection; Nissin Pharmaceutical, Yama-
gata, Japan) was administered to provide
70e75 kcal/kg/d.8
Prevention of infection
Bacterial infectionwas determined based
on a positive finding of bacteremia by
microbial cultures. Meropenem (15 mg/
kg/dose, Ranbaxy; Sydney, Australia)
was administered intravenously to the
fetuses every 6 hours. Intravenous flu-
conazole (4 mg/kg/dose, Fluconazole-
Claris; AFT Pharmaceuticals Pty Ltd,
Sydney, Australia) was administered to
the fetuses every 24 hours.8
Collection of maternal blood for
fetal transfusion
Meropenem (1 g/dose) was adminis-
tered to each ewe after induction of
anesthesia; 100 mL (approximately 2%
e3% of total circulating blood volume
for ewes) was aseptically collected from
the jugular vein before surgery. Whole
blood was immediately heparinized and
then used for priming of the artificial
placenta circuit. A further 300e400 mL
of whole blood was collected after fetal
delivery using a triple-bag blood trans-
fusion system (T331150, Fresenius Kabi,
Mount Kuring-Gai, Australia). Packed
red cells were preserved at 4C before
use. Fresh plasma was frozen at 80C
and defrosted and warmed to physio-
logical temperature on demand.
Ex vivo uterine environment
therapy system components
Artificial placenta. The circuit was
composed of 3 main parts: (1) outflow
tubes, (2) membranous oxygenators,
and (3) an inflow tube (Nipro Corpo-
ration, Osaka, Japan). Only 1 membra-
nous oxygenator per EVE fetus was used.
Heparinized polyvinyl chloride tubes755.e4 American Journal of Obstetrics & Gynecolwere used for both the inflow and
outflow tubes. The circuit was primed
with 50 mL of heparinized maternal
blood. Lipo-PGE1 was mixed in the cir-
cuit priming to prevent umbilical vessel
and ductal contraction (100 ng/mL;
Sawai Pharmaceutical, Osaka, Japan).
The calculated membrane surface area
for gas exchange was 0.15 m2. Extracor-
poreal pumps were not used to maintain
the circuit flow.
Amniotic fluid. Synthetic AF was
aseptically prepared as follows: pH,
7.340.15; Naþ, 1104 mEq/L; Cl,
1114 mEq/L; Kþ, 6.50.8 mEq/L;
Ca2þ, 1.40.3 mEq/L; meropenem, 167
mg/L; fluconazole, and 3.3 mg/L (all
values represent group meanstandard
deviation [SD]). AF was preheated to
39.5Ce40.0C and UV treated for a
minimum of 6 hours before addition to
the AF bath. The AF bath was filled with
synthetic AF (6 L) and warmed
constantly by 2 heaters. Heaters were
installed at the top (radiant warmer) and
at the bottom (contact heat pad) of the
AF bath. After the fetus was submerged,
AF was maintained at a constant tem-
perature of 38.7C0.3C (group
meanSD). To minimize the risk of
microbial colonization, a transparent,
sterilized plastic bag was used to contain
the AF bath. The AF bath was rinsed and
replaced every 6 hours after the start of





Fetal heart rate (HR) and mean arterial
pressure were continuously monitored
and recorded using a SurgiVet monitor
(Smiths Medical, St. Paul, MN). Circuit
blood flow (mL/min) was continuously
monitored using electromagnetic flow
sensors (Transonic 400-Series, Tran-
sonic Systems Inc, Ithaca, NY) attached
to the arterial positions of the blood
circuit and recorded using a PowerLab
(ADInstruments, Dunedin, New Zea-
land). Fetal umbilical arterial blood gases
(pH, base excess [BE]), pCO2, pO2, O2
saturation (SO2), O2 content (CtO2),
sodium ion (Naþ), potassium ion (Kþ),ogy NOVEMBER 2020calcium ion (Ca2þ), and chloride ion
[Cl]); hemoglobin, lactate, and glucose
level (Siemens RAPIDPoint 500,
Munich, Germany); and activated clot-
ting times (Hemochron Jr, Accriva Di-
agnostics, San Diego, CA) were
measured at least every 6 hours. AF was
collected at surgical delivery. Fetal um-
bilical arterial blood samples were
collected every 24 hours after induction
of EVE therapy.
Hematological analyses (white blood
cell [WBC] counts and differential
leukocyte counts), biochemical param-




[GLDH], blood urea nitrogen [BUN],
total bilirubin, albumin, magnesium
[Mg], phosphorus [P], and BUN to
creatinine ratio), endocrine parameters
(cortisol, adrenocorticotropic hormone
[ACTH], and insulin-like growth factor
1 [IGF-1]), and microbiological analysis
(anaerobic and aerobic cultures) were
performed by an independent clinical
pathology laboratory (Vetpath, Perth,
Australia). To prevent hypoxia due to
anemia, all sampling was made volume
neutral through addition of packed red
blood cells and FFP. Packed red blood
cell transfusion generated with maternal
blood was performed (10 mL/kg/time)




Ultrasound assessments were performed
by a single operator to confirm normal
fetal cardiac function at 48 hours after
LPS injection (before surgeries for EVE
animals) and to assess fetal cardiac
function before euthanasia. Measure-
ments were conducted with a Philips
CX50 system, S5-1 phased array probe
(Philips Healthcare, the Netherlands)
and associated obstetrics software. For
control animal measurements, ewes
were held in a dorsal recumbency and
the fetal position from the ventral aspect
was confirmed. The ultrasound beam
was focused to obtain a basal 4-chamber
view, 5-chamber view, left ventricular
outflow tract view, right ventricular
ajog.org OBSTETRICS Original Researchoutflow tract view, or 3 vessel (3V) view
to check the following items.8,27
Briefly, transtricuspid and transmitral
inflow were measured using Doppler
echocardiography to assess the peak
early filling (E wave) and late diastolic
filling (A wave) velocities in calculation
of each E:A ratio. Cardiac time intervals
such as isovolumetric contraction time
(ICT), ejection time (ET), and iso-
volumetric relaxation time (IRT) were
measured for the right and left ventri-
cles. Myocardial Performance Index
(MPI) was calculated using the formula
MPI¼ICTþIRT/ET.
Pulsed Doppler tracings were ob-
tained at the point of the inferior vena
cava orifice entering the right atrium.
Peak velocity during atrial contraction
(A), which frequently has reversed blood
velocities away from the heart, and peak
velocity during ventricular systole (S)
were measured from the recorded flow
velocity waveform, and the A:S ratio was
calculated to obtain the preload index
(PLI).
The inner diameter (D) of the aorta
and the pulmonary artery was measured
at an insonation angle perpendicular to
the vessel wall, between the open semi-
lunar valves. The systolic velocity time
integral (TVI) and HRwere calculated as
an average of 4e6 cardiac cycles. Left and
right ventricular output were calculated
as p $ (D/2)2 $ TVI $ HR. The cardiac
output (CO) was calculated as the sum
of the two, and the corrected CO was
calculated by dividing this by the fetal
weight.35
Color flow Doppler imaging was used
to detect the blood flow direction
through the ductus arteriosus. Blood
flow from the pulmonary artery to the
descending aorta was determined as
right to left directional flow. These
measurements were performed before
euthanasia.
Lipopolysaccharide control group
Eight Merino cross ewes with timed, and
singleton pregnancies were given IA LPS
injection (10 mg) at a GA of 92e93 days.
After 7 days of ultrasound assessments,
they were delivered and killed with an
intravenous bolus of pentobarbitone
(160 mg/kg) at a GA of 99e100 days toallow comparative measurement of BW,
CRL, organ weights (lung, brain), tissue
collection (lung for polymerase chain
reaction [PCR], brain for histopatho-
logic analysis), and fetal whole blood and
plasma collection at delivery (immedi-
ately before euthanasia) to perform
blood corpuscle counts, including dif-
ferential leukocyte count and biochem-
ical and cytokine analyses.
Saline control group (BioBank
samples)
Comparative analysis of AF and plasma
MCP-1 concentrations between LPS-
exposed and naive fetal samples was
performed using previously published,
age-matched samples obtained from
saline-exposed catheterized fetuses
drawn from our ovine BioBank.26 Saline
control group blood gas data, WBC
counts, differential leukocyte counts,
plasma for cytokine, lung tissues for
PCR, and brain tissues for histopathol-
ogy presented herein were similarly ob-





MCP-1 protein concentrations were
measured using fetal plasma and AF
samples from EVE group animals taken
48 hours after IA LPS injection.26 Those
values were compared with data from
saline control and LPS control group
animals. At the end of the experimental
period, fetal plasma concentrations of
MCP-1 and tumor necrosis factor alpha
(TNF-a) were also compared between
the EVE group animals and the saline
and LPS control group animals.
Commercial kits from Kingfisher
Biotech (St Paul, MN), with washing
performed on a Biosan plate washer
(Inteliwasher 3D-IW8, Biosan, Riga,
Latvia), were used as previously
described.9 Standards (calibration curve,
R2>0.99) were assayed in triplicate
(average coefficient of variation, 7.8%)
and samples were assayed in duplicate.
The assay limit of detection was <4 pg/
mL; 100 mL of each standard or sample
was incubated overnight (16 hours) at
4C. Assays were performed according toNOVEMBER 2020 Amerithe manufacturer’s instructions, with
absorbance at 450 nm read on a HiPo
MPP-96 microplate photometer (Bio-
san, Riga, Latvia).
RNA extraction and quantitative
polymerase chain reaction
analysis of lung cytokine
expression
Total RNA was extracted with TRIzol
(Life Technologies) from 100 mg of
snap-frozen fetal lung (right lower
lobe).26,36,37 Extracted RNA was treated
with TURBO DNase (Life Technologies)
according to the manufacturer’s in-
structions. RNA template was quantified
using a Qubit 2.0 fluorometer (Life
Technologies) using a broad-range RNA
quantitation kit (Life Technologies).
RNA extracts were diluted in nuclease-
free water (Life Technologies) to a final
concentration of 25 ng/mL.
Ovine-specific PCR primers and hy-
drolysis probes for interleukin (IL)-1b,
IL-6, TNF-a, and MCP-1 (Life Tech-
nologies) were used to perform quanti-
tative PCR. Reactions were performed
on a Viia7 thermocycler (Life Technol-
ogies) using an EXPRESS One-Step Su-
perScript qRT-PCR Kit (Life
Technologies) with 125 ng of DNAse-
treated template fetal tissue RNA in a
total volume of 20 mL according to the
manufacturer’s instructions. Reaction
cycling conditions were 15-minute
reverse transcription at 50C and an
initial denaturation/polymerase activa-
tion at 95C for 20 seconds, followed by
40 cycles of 95C for 3 seconds and 60C
for 30 seconds (data acquisition phase).
Target Cq values were normalized to 18S
rRNA Cq value and expressed as fold
changes relative to pooled control values.
Reaction efficiencies were within limits
proposed in the MIQE guidelines.38 dCq
values were used to perform statistical
analyses for significant differences be-
tween intervention groups vs control
group.
Preterm brain histology
Brain perfusions fixed with formalin
were processed for gross anatomic
investigation.8 The left hemisphere was
sectioned at 5-mm intervals along the
coronal plane from the anterior tocan Journal of Obstetrics & Gynecology 755.e5
Original Research OBSTETRICS ajog.orgposterior surfaces according to the
method by Banker and Larroche.39
Briefly, each 5-mm section was visually
inspected for the presence of abnor-
malities (petechial hemorrhage, focal
coagulation necrosis). Every second 5-
mm section (4 in total) was selected to
be embedded in paraffin; 10-mmsections
were then hematoxylin and eosin (H&E)
stained. Sections were evaluated for the
presence of pathologic lesions by a single
investigator. WMI was defined as the
presence of focal coagulation necrosis
and cellular infiltration localized within
the deep white matter or peripheral to
the lateral ventricles. Six nonoverlapping
fields (40 total magnification) were
assessed for each section.
Statistical analyses
IBM SPSS for Windows version 23.0
(IBM Corporation, Armonk, NY) was
used for statistical analyses. A chi-square
test was used to test the differences of
nominal values between 2 groups. All
numerical data were tested for normality
using Shapiro-Wilk tests. Extreme out-
liers were tested for exclusion with
Smirnov-Grubbs tests. In the compari-
son of 2 groups, between-group differ-
ences in parametric data were tested for
significance using t-tests, whereas
Mann-Whitney U tests were used for
nonparametric data. In the comparison
of more than 2 groups, between-group
differences in parametric data were
tested for significance using one-way
ANOVA, whereas Kruskal-Wallis tests
were used for nonparametric data.
Multiple post hoc comparisons were
performed with Tukey or Dunnett tests.




Eight of 10 fetuses in the EVE group and
6 of 8 fetuses in the LPS control group
completed a predetermined 120-hour
experimental period (Table 1). Key
physiological data are presented in
Figure 1. One experimental fetus
(Figure 1, H) was excluded from general
group comparison (Table 1) because of
the presence of severe growth restriction
(outlier; 494 g at 100-dayGA). Another 2755.e6 American Journal of Obstetrics & Gynecolfetuses were killed 24 hours and 36 hours
after initiation of EVE therapy because of
acute circuit failure (catheter flow was
obstructed by intense fetal movement)
andwere excluded from further analyses.
Fetal BW and lung weight were
significantly lower and CRL was signifi-
cantly shorter in EVE group animals
than in LPS control group animals.
There were no significant differences in
GA, sex ratio, weight-corrected CRL,
weight-corrected lung weight, brain
weight, and weight-corrected brain
weight at the conclusion of the 120-hour
study between the LPS control and EVE
group animals over the experimental
period (Table 1).
For EVE group animals, cord blood
gas data had pO2 values within the target
range (15e30 mm Hg). pH, pCO2, BE,
SO2, O2, CtO2, Na
þ, Kþ, Ca2þ, Cl,
hemoglobin, lactate level, glucose, and
activated clotting time also remained
clinically acceptable and within an ex-
pected reference range (Table 2).
Statistically, AST, ALT, GGTP, GLDH,
and BUN levels and the BUN to creati-
nine ratio were modestly but signifi-
cantly higher in EVE group animals than
those in the LPS control group animals,
whereas no difference was found in total
bilirubin, albumin, Mg, and P value.
Creatinine level was significantly lower
in EVE group than that in the control
group at 120 hours (Table 3). Similar
findings were seen in our previous work
with this model, and the biological
relevance of these modest changes re-
mains unclear.
Plasma cortisol concentrations in EVE
group animals were significantly
increased over the 120-hour period of
EVE therapy compared with values taken
at the start of experiments (0 hour).
Cortisol concentrations at the end of
experiment in EVE group animals were
significantly higher than those in the LPS
control group animals (Figure 2, A).
Plasma concentrations of ACTH in EVE
group animals were significantly
decreased over the 120-hour experi-
mental period compared with values
measured at 0 hour. ACTH concentra-
tions taken at the end of experiments
(120 hours) in EVE group animals were
significantly lower than those in the LPSogy NOVEMBER 2020control group animals (Figure 2, B). In
EVE group animals, plasma concentra-
tions of IGF-1 were significantly
decreased at 48, 72, 96, and 120 hours
compared with measurements taken at
0 hour. IGF-1 concentrations at the end
of experiment in EVE group animals
were significantly lower than those in the
LPS control group animals (Figure 2, C).
Ultrasound analysis for viability 48
hours after LPS injection confirmed fetal
cardiac function in all LPS control and
EVE group animals. For ultrasound as-
sessments performed before euthanasia,
there was no significant difference in
tricuspid andmitral valve E:A ratio, right
and left MPI, PLI, and corrected CO
between the LPS control and EVE group
animals. The direction of flow through
the ductus arteriosus was from right to
left in each of 8 EVE group animals
(Table 4).
Individual case information (Figure 1,
AeH) is as follows (Table 5):
Ex vivo uterine environment
group animals 1 and 2 (cases A
and B)
All measured physical variables
remained within the respective reference
ranges. Normal intermittent active fetal
swallowing movements, breathing
movements, gross fetal body move-
ments, and flexure and extension of
limbs were observed throughout the
assessed period. There were no edema,
ascites, pleural effusion, and bleeding.
Brain injuries (hemorrhage and WMI)
were not detected histopathologically.
No bacteria were identified from blood
and AF cultures.
Ex vivo uterine environment
group animal 3 (case C)
Blood pressure and total circuit flow
sharply decreased from 1 hour after in-
duction of EVE therapy and was
controlled by 3 doses of Dex (total¼0.45
mg) in addition to the predetermined
treatment (volume load and primary HC
administration). All measured physical
parameters were subsequently main-
tained within respective reference ranges
for the first 60 hours. Normal intermit-
tent active fetal swallowing movements,
breathing movements, gross fetal body
TABLE 1
Comparison of fetal data at necropsy
Variable LPS control group EVE group Statistical test P value
Planned number 8 10
Survival number 6 8
Number for statistics 6 7
Gestational age at LPS injection (d) 92.80.8 92.10.7
Gestational age at induction of EVE therapy (d) - 94.10.7
Gestational age at conclusion (d) 99.80.8 99.10.7 t-test .122
Sex (male/female) 0.5 3/4 Chi-square test .383
Body weight (g) 1051 [973e1090] 869 [816e883]a Mann-Whitney U test .035
Crown-rump length (cm) 32.11.0 30.31.2a t-test .013 [3.14 to .46]
Weight-corrected crown-rump length (cm/kg) 31.11.8 34.54.5 t-test 118
Lung weight (g) 38.71.2 34.82.5a t-test .004 [6.33 to 1.5]
Weight-corrected lung weight (g/kg) 37.62.7 39.65.7 t-test .444
Brain weight (g) 26.51.6 25.11.0 t-test .093
Weight-corrected brain weight (g) 25.1 [23.3e27.0] 28.7 [22.6e 30.0] Mann-Whitney U test .101
Respective values are expressed as group meanSD and significant P values with 95% confidence interval were indicated for t-test. Respective values are expressed as mean [interquartile range] for
Mann-Whitney U test. Significant difference vs value for the control group is indicated.
EVE, ex vivo uterine environment; LPS, lipopolysaccharide.
a P<.05.
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of limbs were observed in the first 60
hours. Circuit flow was interrupted for
approximately 5 minutes with an unex-
pected occlusion of catheter flow at 60
hours after EVE therapy. Circuit flow
was restored with changes in catheter
position and angle. To prevent further
deterioration in circuit performance,
fetal movement was reduced through
intravenous midazolam administration
(0.15 mg/kg/h) until the end of the
experimental period. There was no evi-
dence of pleural effusion and bleeding,
although there was slight edema and
ascites. The review of H&Eestained
coronal sections (mammillary bodies
level) revealed the presence of focal
coagulation necrosis and cellular infil-
tration consistent with periventricular
leukomalacia. No bacteria were identi-
fied from blood and AF cultures.
Ex vivo uterine environment
group animal 4 (case D)
Blood pressure and total circuit flow
sharply decreased from 30 minutes afterthe induction of EVE therapy and was
controlled by 3 doses of Dex adminis-
tration (total¼0.45 mg) in addition to
the predetermined treatment. All
measured physical variables subse-
quently remained within the desired
reference ranges. Normal intermittent
active fetal swallowing movements,
breathing movements, gross fetal body
movements, and flexure and extension
of limbs were present throughout the
assessed period. There were no edema,
ascites, pleural effusion, and bleeding.
The review of H&Eestained coronal
sections (anterior basal ganglia level)
revealed the presence of focal coagula-
tion necrosis and cellular infiltration
consistent with periventricular leuko-
malacia. No bacteria were identified
from blood and AF cultures.
Ex vivo uterine environment
group animal 5 (case E)
Blood pressure and total circuit flow
sharply decreased from 1.5 hours after
induction of EVE therapy and was
controlled by 2 doses of DexNOVEMBER 2020 Ameriadministration (total¼0.3 mg) in addi-
tion to the predetermined treatment. All
measured physical variables subse-
quently remained within the desired
reference ranges. Normal intermittent
active fetal swallowing movements,
breathing movements, gross fetal body
movements, and flexure and extension
of limbs were present throughout the
assessed period. There were no edema,
ascites, pleural effusion, and bleeding.
There were no histopathologic brain
injuries. No bacteria were identified
from blood and AF cultures.
Ex vivo uterine environment
group animal 6 (case F)
Blood pressure and total circuit flow
sharply decreased from 0.5 hours after
induction of EVE therapy and was
controlled by 2 doses of Dex adminis-
tration (total¼0.3 mg) in addition to
the predetermined treatment. All
measured physical parameters were
subsequently maintained within the
respective reference ranges in the first
108 hours. Normal intermittent activecan Journal of Obstetrics & Gynecology 755.e7
FIGURE 1
Changes in fetal physiological and biochemical variables over time in the EVE group
The horizontal axis represents the time after induction of ex vivo uterine environment therapy (hours). The black solid lines show total oxygenator (circuit)
blood flow (mL/kg/min); the gray solid lines show heart rate (beats/min); the gray dotted lines show mean arterial pressure (mm Hg); the black closed
triangles show SO2, arterial oxygen saturation (%); the black closed circles show pCO2 (Torr); and the black closed squares show Lac, blood lactate level
(mmol/L). Only the blood lactate levels use the right scale bar. The timing of refractory hypotension is also depicted (black arrows).
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TABLE 2
Blood gas data throughout the experiments in the EVE group
Variable Reference EVE
pH 7.380.03 7.390.05
Base excess (mmol/L) 0.21.8 0.83.6
pCO2 (Torr) 42.42.9 43.63.8
pO2 (Torr) 25.12.1 27.93.8
SO2 (%) 65.55.9 64.47.9
CtO2 (mmol/L) 8.91.2 9.21.3
Hemoglobin (g/L) 939 1055
Glucose level (mmol/L) 1.60.2 3.21.3
Lactate level (mmol/L) 1.70.4 1.60.9
Naþ (mmol/L) 1343.1 1435.7
Kþ (mmol/L) 4.00.3 3.50.5
Ca2þ (mmol/L) 1.40.1 1.30.1
Cl (mmol/L) 1031.7 1126.0
Activated clotting time (s) — 20324
Eight EVE group animals were analyzed throughout the experiment. Umbilical arterial blood was collected for blood gas data
every 6 hours after the start of EVE therapy. Values are expressed as group meanstandard deviation.
The reference data were obtained from 13 age-matched (972 days gestational age), null-treatment fetuses, which were
previously collected for our ovine databank.
Ca2þ, calcium ion; Cl, chloride ion; CtO2, O2 content (hemoglobin (g/dL)  1.34  SpO2 (%)/100þ pO2  0.003); EVE,
ex vivo uterine environment; Kþ, potassium ion; Naþ, sodium ion; SO2, O2 saturation.
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ajog.org OBSTETRICS Original Researchfetal swallowing movements, breathing
movements, gross fetal body move-
ments, and flexure and extension of
limbs were observed in the first 108
hours. After this time, the circuit flow
started to fluctuate in response to fetal
active movements and posture changes.
To prevent further deterioration in cir-
cuit performance, fetal movement was
reduced through intravenous mid-
azolam administration (0.15 mg/kg/h)
until the end of the experimental
period. There were no ascites, pleural
effusion, and bleeding, although there
was slight edema. There were no histo-
pathologic brain injuries. No bacteria
were identified from blood and AF
cultures.
Ex vivo uterine environment
group animal 7 (case G)
Blood pressure and total circuit flow
sharply decreased from 0.5 hours after
induction of EVE therapy and was
controlled by 2 doses of Dex admin-
istration (total¼0.3 mg) in addition to
the predetermined treatment. All
measured physical variables subse-
quently remained within the respective
reference ranges. Normal intermittent
active fetal swallowing movements,
breathing movements, gross fetal body
movements, and flexure and extension
of limbs were observed throughout the
assessed period. There were no edema,
ascites, pleural effusion, and bleeding.
Brain injuries (hemorrhage and WMI)
were not detected histopathologically.
No bacteria were identified from
blood although Pseudomonas stutzeri
was identified in synthetic AF cultures
taken both from the artificial uterus
and the synthetic AF reservoir (before
administration to the experimental
system) at the conclusion of the
experiment.
Ex vivo uterine environment
group animal 8 (case H)
This fetus had growth restriction, with
fetal BW (494 g), height (24 cm),
and weight-corrected brain weight
(45.3 g/kg) at the conclusion of the
study. Blood pressure and total circuit
flow sharply decreased from 0.5 hours
after induction of EVE therapy and wascontrolled by 2 doses of Dex adminis-
tration (total¼0.6 mg) in addition to
the predetermined treatment. All
measured physical variables subse-
quently remained within the respective
reference ranges. Normal intermittent
active fetal swallowing movements,
breathing movements, gross fetal body
movements, and flexure and extension
of limbs were observed throughout the
assessed period. There were no edema,
ascites, pleural effusion, and bleeding.
The review of H&Eestained coronal
sections (anterior basal ganglia level)
revealed the presence of focal coagula-
tion necrosis and cellular infiltration
consistent with periventricular leuko-
malacia. No bacteria were identified
from blood, although Pseudomonas
stutzeri was identified in synthetic AF
cultures taken both from the artificial
uterus and the synthetic AF reservoir
(before administration to the experi-
mental system) at the conclusion of the
experiment.NOVEMBER 2020 AmeriEx vivo uterine environment group
infection and inflammation
Although the plasma concentration of
MCP-1 in LPS control and EVE group
animals was significantly higher than
that in the saline control group animals,
no difference was found between EVE
and LPS control group animals
(Figure 3, A). Similarly, AF concentra-
tion of MCP-1 in LPS control and EVE
group animals was significantly higher
than that in the saline control group
animals (Figure 3, B).
Evaluation of infection and
inflammatory response at the end
of experimental period (120 hours
after ex vivo uterine environment or
168 hours after lipopolysaccharide
injection for the control)
No bacteremia was found from blood
cultures in any of the 8 EVE group ani-
mals, although Pseudomonas stutzeri was
grown from the AF cultures in 2 EVE
group animals (cases G andH) at the endcan Journal of Obstetrics & Gynecology 755.e9
TABLE 3
Comparison of fetal chemical data at 120 hours
Variable LPS control group EVE group Statistical test P value
AST (U/L) 24 [22e28] 56 [40e138]a Mann-Whitney U test .003
ALT (U/L) 3.0 [2.2e3.0] 9.5 [6.8e5.0]a Mann-Whitney U test .008
GGTP (U/L) 229 4816a t-test .012 [7e45]
GLDH (U/L) 10 [5e17] 17 [40e138] a Mann-Whitney U test .012
Total bilirubin (mg/dL) 1.90.5 2.41.9 t-test .105
Albumin (g/dL) 1.90.1 2.00.2 t-test .247
BUN (mg/dL) 13.53.2 20.36.5a t-test .03 [.8e12.8]
Creatinine (mg/d/L) 0.870.14 0.530.17a t-test .001 [0.53 to .16]
BUN/Cre ratio 15.74.6 38.04.1a t-test .001 [17.9e29.9]
Mg (mmol/L) 1.20.2 1.10.1 t-test .397
P (mmol/L) 2.20.3 2.00.2 t-test .07
Six LPS control and 8 EVE group animals were analyzed. Respective parametric values are expressed as group meanstandard deviation, and significant P values with 95% confidence interval were
indicated for t-test. Respective nonparametric values are expressed as mean [interquartile range] for Mann-Whitney U test. Significant difference vs value for the control group is indicated.
ALT, alanine aminotransferase, AST, aspartate aminotransferase; BUN, blood urea nitrogen; EVE, ex vivo uterine environment; GGTP, gamma-glutamyl transpeptidase; GLDH, glutamate dehy-
drogenase; LPS, lipopolysaccharide; Mg, magnesium; P, phosphate.
a P<.05.
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There was no significant difference in
plasma concentrations of MCP-1 be-
tween saline negative control, LPS con-
trol, and EVE group animals (one-way
ANOVA; P¼.372), and plasma TNF-a
was not detected in any of the groups
(data not shown).
The number of circulating WBCs in
LPS control and EVE group animals was
significantly higher than that in saline
negative control group animals, whereas
no difference was found between LPS
control and EVE group animals. Simi-
larly, the number of neutrophils in the
LPS control and EVE group animals was
significantly higher than that in saline
negative control group animals; there
was no difference between LPS control
and EVE group animals. There was no
difference in the number of lymphocytes
between any of the groups. The number
of monocytes was higher in LPS control
group animals than that in saline nega-
tive control and EVE group animals
(Figure 4, A).
For lung quantitative PCR, no signif-
icant differences in the relative mRNA
expression of IL-1b, IL-6, TNF-a were
identified between saline negative755.e10 American Journal of Obstetrics & Gyneccontrol, LPS control, and EVE group
animals. The relative mRNA expression
of MCP-1 in LPS control group animals
was significantly higher than that in sa-
line negative control and EVE group
animals (Figure 4, B).
Brain histopathology
Three LPS control and 3 EVE group
animals had WMI in H&Eestained
coronal sections (anterior basal ganglia
level or mammillary bodies level),
whereas noWMIwas found in any of the
9 saline negative control group animals.
There was no evidence of hemorrhage or
WMI in any of the remaining LPS con-
trol, EVE, or saline negative control
group animals in gross anatomic and
H&Eestained histopathologic analyses
of coronal brain sections (Figure 5).
Comment
The primary finding of this study is that
EVE tallowed a 120-hour period of sur-
vival in a group of 8 extremely preterm
lambs compromised by a 48-hour ante-
natal exposure to intrauterine inflam-
mation (Figures 1 and 3; Table 6). To our
knowledge, this is the first report of an
artificial placentaebased life supportology NOVEMBER 2020system being used to sustain extremely
preterm fetuses (400e700 g), compro-
mised by exposure to intrauterine
inflammation—a common antecedent
of extremely preterm delivery. Fetal
growth restriction was observed in EVE
group animals compared with LPS pos-
itive control (in utero) group animals,
although EVE group animals were
otherwise stable from a hemodynamic
viewpoint after acute intensive manage-
ment (Figure 1, Tables 1e3 and 5) and
did not present evidence of altered car-
diac parameters by ultrasound (Table 4).
This is a particularly important finding
as, ideally, fetal growth should be main-
tained as close to normal as possible in
an artificial placenta platform. Given the
differences in somatic growth and hor-
mone concentrations identified in the 3
study groups, it appears that the
observed growth restriction derives from
an as-yet unidentified deficiency in our
EVE therapy system, rather than LPS
exposure itself.
All animals were free of bacteremia,
and no additional systemic inflamma-
tory changes were detected at the
conclusion of treatment in the EVE
group animals compared with LPS
FIGURE 2
Changes in the concentrations of cortisol, adrenocorticotropic hormone, and insulin-like growth factor 1 over time in
the EVE group and comparisons between EVE and control groups at the end of the study
Six lipopolysaccharide positive control animals and 8 EVE group animals were analyzed for plasma concentrations of cortisol (panel A), adrenocorti-
cotropic hormone (panel B), and insulin-like growth factor 1 (panel C). The horizontal axis represents the time after the induction of ex vivo uterine
environment therapy (hours). All values are presented as bar charts with group mean and with whiskers representing standard deviation. Gray bar
indicates EVE group animals. Black bar indicates control animals. Differences of values over time in EVE group animals were tested for significance using
repeated one-way analysis of variance. Multiple post hoc comparisons were performed using Dunnett test compared with the value at 0 hour; The *
symbol indicates P<.05 accepted as significant. Differences of values at the end of the experimental period between EVE and control group animals were
tested using t-test; The ysymbol indicates P<.05 accepted as significant.
CT, control; EVE, ex vivo uterine environment.
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Tables 5 and 6). Although a treatment
time of 120 hours may be limited in
terms of clinical use, data from this study
show the potential of EVE therapy as a
clinical platform for extremely preterm
infants exposed to intrauterine
inflammation.
Maintenance of key physiological
parameters
Key physiological parameters and blood
lactate levels generally remained within
their reference ranges, or rapidly
returned to reference range after EVE
therapy was started and/or refractory
hypotension was successfully treated
(Figure 1; Table 2). Total lung flow vol-
ume was maintained within normal
range (150e300 mL/kg/min), which wassimilar to that shown by our previous
study using extremely preterm lamb
model.8 Although fetal hypoxia
(pO2<20 Torr) is likely to be induced by
LPS and reported to become a factor of
brain injury,40,41 pO2 and CtO2 were
maintained within a reference range at
least after the induction of EVE therapy
(Table 2). However, refractory hypoten-
sion and the subsequent transient
elevation of lactate level might reflect
fetal ischemic changes (Figure 1).
Ultrasound data
The main aim of these ultrasound mea-
surements was to determine cardiac
dysfunction in EVE therapy animals, and
the reference range was described in a
previous report using extra preterm
lamb model.8 Differences in any itemsNOVEMBER 2020 Americbetween LPS control and EVE group
animals were not demonstrated, and the
values of all items in both group animals
were within the reference range. Fetal
circulation (R/L direction through the
ductus arteriosus) was maintained with
EVE therapy over the 120-hour experi-
mental period.
Infection and inflammation
All animals were free of bacteremia
throughout the experiment. In terms of
inflammation at 48 hours after IA LPS
injection, MCP-1 has been reported to
be significantly increased both in plasma
and AF for extremely preterm fe-
tuses.25,26 MCP-1 was evaluated as an
indicator of inflammation. EVE group
animals had a significant increase in
MCP-1, which was equivalent to that ofan Journal of Obstetrics & Gynecology 755.e11
TABLE 4
Comparison of fetal cardiac ultrasound data at study conclusion
Variable LPS control group EVE group P value
Tricuspid valve E:A ratio 0.720.08 0.680.08 .414
Mitral valve E:A ratio 0.680.11 0.660.08 .774
Right Myocardial Performance Index 0.430.04 0.430.08 .417
Left Myocardial Performance Index 0.410.03 0.420.03 .99
Preload index 0.350.12 0.380.14 .67
Corrected cardiac output (mL/min/kg) 53060 511122 .74
Direction of ductus arteriosus flow Right / left Right / left
Six LPS control and 8 EVE group animals were analyzed. Respective values are expressed as group meanstandard deviation. t-test was conducted for statistical analysis. P<.05 was considered as
significant difference. Blood flow from the pulmonary artery to the descending aorta was determined as right to left directional flow.
EVE, ex vivo uterine environment; LPS, lipopolysaccharide.
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(Figure 3, A and B). Thus, intrauterine
inflammation was induced by IA LPS
injection, and EVE surgery and platform
maintenance could be conducted using
extremely preterm lambs compromised
by intrauterine inflammation.
WBC and neutrophil levels increased
both in LPS control and EVE group an-
imals and were equivalent at the end of
the 120-hour experimental period
(Figure 4, A). Reportedly, in preterm
sheep, peripheral WBC and neutrophil
levels increased over 4e7 days after IA
LPS exposure. WBC counts then
returned to control levels by 15 days,
whereas neutrophils counts remained
increased at 14 days after LPS
exposure.42e44 Thus, this increase of
WBCs and neutrophils seemed not to be
induced by additional infection but by
the IA LPS injection.
MCP-1 transcript expression in lung
tissues of LPS control group animals was
significantly higher than that of saline
negative control and EVE group animals
at the conclusion of the experiment,
whereas all other measured transcripts
returned to baseline (Figure 4, B). In
preterm fetal sheep, IA LPS injection
induces large increases of proin-
flammatory cytokine responses in the
fetal lung.25,26 Those inflammatory re-
sponses (IL-1b, IL-6, TNF-a) are re-
ported to return to baseline by 7e15
days after IA injection,44 and our data
suggest that the adaptation of755.e12 American Journal of Obstetrics & Gyneccompromised extremely preterm fetuses
to EVE therapy does not exacerbate
existing inflammation or gross brain
injury.
Success rate
The survival rate with EVE therapy was
80%, whereas that with the control ani-
mals was 75% (Table 6). Two EVE ani-
mals died because of catheter-based
circuit compromise. Two control animals
also died owing to unidentified reasons.
Reportedly, intravenous LPS injection
causes fetal systemic inflammation,
thereby leading to fetal death.45 However,
fetal death due to IA LPS injection has not
been reported in extremely early GA ex-
periments, although this may be due to
more abbreviated study periods being
reported.25,26,46 In this study, no fetal
death was detected by ultrasound in
either the LPS positive control or EVE
group animals during the first 48 hours
after IA LPS injection.
Limitations
The primary limitation of this study is the
small sample size and short trial period.
As previously described, a 5-day mainte-
nance period was selected based on
several considerations. First, balancing
the substantial amount of infrastructure
and constant monitoring limits the sam-
ple number achievable.8 Second, as this
was the first attempt to adapt extremely
preterm fetuses compromised by intra-
uterine inflammation to an artificialology NOVEMBER 2020placenta system, we elected to limit the
duration of the experiment to 5 days,
allowing us to establish the acute efficacy
of our system.8
Although we assessed a range of key
physiological and hematological vari-
ables in determining fetal well-being
over the 120-hour experiments, we did
not perform comprehensive assessments
of organ development. Given the nature
of the experimental design, it was also
not possible to assess the hemodynamic
impact of IA LPS on LPS control group
animals without incorporating addi-
tional surgical interventions. We elected
not to pursue this approach in this study
because we wished to focus on the
comparison of fetal development in the
absence of potential confounding from
fetal surgery necessary to introduce
catheters and monitoring probes; future
studies may require the addition of an
instrumented LPS control group along
with a noninstrumented group.
The use of glucocorticoids appears to
be essential for current EVE therapy in
the maintenance of extremely preterm
lambs at the border of viability, although
it is also well known that the use of
glucocorticoids to premature fetuses af-
fects maturation of vital organs such as
the brain and lungs, inflammatory
markers, and death.47e50 It is also worth
noting that glucocorticoids are also
effective anti-inflammatory agents,
which should be taken into account
when assessing the inflammatory data
TABLE 5
Case summary of EVE group animals
EVE animals EVE 1 (A) EVE 2 (B) EVE 3 (C) EVE 4 (D) EVE5 (E) EVE 6 (F) EVE 7 (G) EVE 8 (H)
Swallowing movement þ þ (24e62 h)þ þ þ (24e108 h)þ þ þ
Breathing movement þ þ (24e62 h)þ þ þ (24e108 h)þ þ þ
Gross body movements þ þ (24e62 h)þ þ þ (24e108 h)þ þ þ
Flexure and extension of limbs þ þ (24e62 h)þ þ þ (24e108 h)þ þ þ
Edema - - þ - - þ - -
Ascites - - þ - - - - -
Pleural effusions - - - - - - - -
Total dose of dexamethasone
administration to control refractory
hypotension (mg)
- - 0.45 0.45 0.3 0.3 0.3 0.6
Brain bleeding - - - - - - -
White matter injury - - þ þ - - - þ
Blood culture - - - - - - - -
Culture from AF in artificial womb - - - - - - Pseudomonas
stutzeri
Pseudomonas stutzeri
AF culture - - - - - - Pseudomonas
stutzeri
Pseudomonas stutzeri
Specified issue - - Circuit trouble owing
to a kink at the tip
of the catheters
- - Circuit trouble
owing to a kink









The þ symbol indicates present and e indicates absent.
Normal intermittent active fetal swallowing movement, breathing movements, gross fetal body movements, and flexure and extension of limbs were assessed at least every 6 hours. Edema, ascites, pleural effusion, bleeding, and another specific issue were identified
during necropsy after 120 hours of EVE therapy. White matter injury was identified in hematoxylin and eosinestained coronal sections. Samples for culture bottles were collected from fetal umbilical artery, synthetic AF in artificial womb, and sterilized tubes at the end
of the experimental period.
AF, amniotic fluid; EVE, ex vivo uterine environment.



































Comparison of concentration values of monocyte chemoattractant protein 1 in fetal plasma and amniotic fluid at 48
hours after lipopolysaccharide (LPS) injection
Nine saline negative control (saline treatment was conducted at a gestational age of 93 days), 9 LPS control (LPS treatment was conducted at a gestational
age of 93 days), and 8 ex vivo uterine environment (EVE) group animals (LPS treatment was conducted at a gestational age of 93 days) were analyzed. Panel
A shows the comparison of fetal plasma concentration and panel B shows the comparison of amniotic fluid concentration of monocyte chemoattractant
protein 1. All values are presented as bar charts with groupmean and with whiskers representing standard deviation. The white bars indicate negative control
group. The black bars indicate the positive control group. The gray bars indicate the EVE group. Differences of values between the groups were tested for
significance using one-way analysis of variance. Multiple post hoc comparisons were performed using Turkey test. The y symbol indicates P<.05 accepted
as significant.
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important as the LPS control group an-
imals were not exposed to steroids or
antibiotics, both of which have the po-
tential to modulate inflammatory and
injury responses. Given the potential for
glucocorticoid-induced changes to fetal
development, extensive assessments of
optimal dosing and the impact of glu-
cocorticoids on inflammation and
growth will be key elements of future
studies; such analyses will be facilitated
by long-term studies using our refined
EVE therapy system and will be essential
to demonstrate the clinical utility of this
concept for the management and sup-
port of extremely preterm infants.
An additional limitation of impor-
tance is the inflammatory stimuli
employed. This study used LPS, which is
a sterile modulator of toll-like receptor 4
signaling. It has the advantage of deliv-
ering a standardized, albeit self-limited,
proinflammatory response. However, it
neither faithfully replicates the poly-
valent stimulation derived from an active
microbial or fungal infection of the
uterus nor facilitates fetal sepsis, which is
similarly associated with extremely755.e14 American Journal of Obstetrics & Gynecpreterm delivery.51,52 Delivery timing
was set at 48 hours after IA LPS injection
based on previous studies.25,26,43,44
Although this setting would enable us
to evaluate if the induction of EVE
therapy in extremely preterm lambs
exposed to intrauterine inflammation
was feasible, it might not be appropriate
to evaluate the resolution of fetal in-
flammations because many inflamma-
tory responses induced by IA LPS return
to the standard level in 7 days.43,44
Challenges yet to be overcome for
clinical application
Refractory hypotension
In this study, HC was administered to
manage refractory hypotension after the
induction of EVE therapy.8 However,
hypotension (which could be managed
comparatively easily in previous studies
using LPS-naive fetuses) could not be
easily controlled even with the use of
additional volume expansion and HC
administration in the majority of EVE
group animals exposed to intrauterine
inflammation (EVE 1e8). Profound re-
fractory hypotension in a number of
these animals occurred within the first 3ology NOVEMBER 2020hours after the induction of EVE ther-
apy. Although total lung flow and blood
pressure were initially maintained within
the reference range after adaptation to
EVE therapy, both metrics started to
degrade shortly thereafter.
Hypotension is frequently identified
in preterm infants, and its incidence is
inversely related to GA at delivery likely
because of a host of factors such as
immature myocardium, immature
autonomic nervous system, and relative
adrenal insufficiency.53e60 Approxi-
mately 25% of ELBW infants with hy-
potension do not respond to either
volume expansion or inotropic drug and
are treated by HC, independent of serum
cortisol concentrations, to normalize
blood pressure.61e63 In our study, HC
treatment and volume expansion were
insufficient for a number of EVE group
animals exposed to intrauterine inflam-
mation to recover from refractory hy-
potension. Although the mechanism for
this is unclear, it may be because cho-
rioamnionitis also releases inflammatory
mediators that increase vascular perme-
ability and vasodilation and in doing so
predispose the fetus to refractory
FIGURE 4
Differential cell counts (blood) and cytokine mRNA expression (lung) at the end of the experiment
Nine saline negative (saline treatment; data taken from our ovine bank age-matched at 99.90.7 days of gestational age), 6 lipopolysaccharide (LPS)
control, and 8 ex vivo uterine environment (EVE) group animals were analyzed. Panel A, white blood corpuscles. All values are presented as bar charts
with group mean and with whiskers representing SD. The white bars indicate the saline negative control group. The black bars indicate the LPS control
group. The gray bars indicate the EVE group. Differences of values between the groups were tested for significance using one-way analysis of variance.
Multiple post hoc comparisons were performed using Turkey test. The y symbol indicates P<.05 accepted as significant. In panel B, tumor necrosis
factora and monocyte chemoattractant protein 1. Relative fold changes in cytokine (interleukin-1b, interleukin-6, tumor necrosis factora, and monocyte
chemoattractant protein 1) mRNA expression in lung tissue samples. All values are presented as box plots with group median and with whiskers
representing maximum and minimum values. White box indicates saline negative control group and black box indicates LPS control group animals. Gray
box indicates EVE group animals. Respective differences of values were tested for significance using Kruskal-Wallis test. Multiple post hoc comparisons
were performed using Turkey test. The y symbol indicates P<.05 accepted as significant.
IL, interleukin; MCP-1, monocyte chemoattractant protein 1; TNF-a, tumor necrosis factor a; WBC, white blood corpuscle.
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istration of the strong glucocorticoid
Dex might improve the clinical picture
by compensating for relative steroid
insufficiency and contributing to
reduced inflammation through its anti-
inflammatory activity. Given the time
scale involved, it is also possible that
several hours are required for the benefit
of glucocorticoid signaling changes to
translate into improvements in physio-
logical parameters and that additional
steroid administration (including Dex)
is unnecessarily excessive.
Although the optimal dose and timing
remains unclear, HC and Dex coadmin-
istration assisted us in achieving the 120-
hour survival time for 8 of 10 EVE group
animals exposed to intrauterine inflam-
mation. However, EVE group animals
still had transient increases in lactate level
after recovery from hypotension. HC and
Dex therapy resulted in high concentra-
tions of fetal cortisol and may have sup-
pressed ACTH secretion (Figure 2, A and
B). Thus, optimization of appropriate
timing and dose and evaluation of long-term effects of glucocorticoid treatment
will become key elements of future work
to minimize adverse effect to growth or
neurodevelopment.
Growth restriction
EVE group animals had growth restric-
tion compared with LPS control animals.
LPS control group animals had ostensibly
normal growth8 despite being subjected
to the same IA LPS exposure as growth-
restricted EVE group animals. These
data suggest that EVE group animals
exposed to intrauterine inflammation are
susceptible to extrauterine growth re-
striction (EUGR), the most frequent
morbidity among premature babies
especially those weighing <1500 g under
current neonatal clinical settings.64,65
The primary cause of EUGR is widely
considered to be nutrient insuffi-
ciency.66,67 Although EVE group animals
were given the same nutrient supple-
mentation,8 that level of support may
not meet the requirements of extremely
preterm lambs exposed to intrauterine
inflammation. The metabolic responseNOVEMBER 2020 Americto and nutritional requirements of sepsis
in the neonate are not well defined;
septic neonates are reported to require
higher-energy delivery during the acute
phase of their illness. In adults, sepsis
alters protein requirements more acutely
by its effect on cytokine-mediated mus-
cle catabolism. A similar requirement
may be observed in extremely preterm
fetuses. No study has assessed whether
provision of extra protein will reduce
this catabolic response for neonates, but
at this point, it seems prudent to provide
at least 2.5 g/kg per day of protein to the
septic infant.68,69 Thus, optimization of
appropriate nutrition for extremely
preterm infants with intrauterine
inflammation may be key for future
treatment.
HC and Dex use also might be a cause
of growth restriction. The use of corti-
costeroids such as HC and Dex has been
established to prevent or reduce chronic
lung injury for premature babies. How-
ever, neonatal Dex has also been associ-
ated with somatic growth impairment,
both during treatment (“early growthan Journal of Obstetrics & Gynecology 755.e15
FIGURE 5
Representative images of brain histology
Six lipopolysaccharide (LPS) control and 8 ex vivo uterine environment (EVE) group animals (EVE 1e8) were analyzed with hematoxylin and eosin (H&E)
stain. Six fields from four 5-mm serial sections were assessed for each animal. Three control and 3 EVE group animals (EVE 3, 4, and 8) had white matter
injury (WMI). Representative image of WMI from 1 of injured LPS positive control group animals (panels A and D) and EVE 4 in EVE group animals (panels B
and E) and representative image of non-WMI from saline negative control group animals (panels C and F) identified in investigation with H&E staining
showing necrosis and cellular infiltration. Images are inspected at100 total magnification (panels AeC) and200 (panels CeF); scale bar represents
100 mm.
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Original Research OBSTETRICS ajog.orgrestriction”)70,71 and at follow-up of
previously Dex-treated newborns at ages
ranging between 2 and 17 years,72e75
whereas no significant effect of post-
natal HC therapy has been found onTABLE 6
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matter injury identified in gross anatomic observation, and
ne environment therapy. Am J Obstet Gynecol 2020.
ajog.org OBSTETRICS Original Researchuse of glucocorticoids will be key for
future studies in this area (Figure 2, A
and B).
IGF-1 values in EVE group animals
were decreased over the experiment and
were significantly lower than that in the
LPS control group animals at the
conclusion of the experiment (Figure 2,
C). Whereas IGF-2 is the primary
growth factor underpinning embryonic
growth, the dominant fetal growth
regulator is IGF-1, produced mainly by
the fetal liver in addition to AF and other
organs.81e83 Umbilical cord IGF-I levels
correlate closely with birthweight and
there has been a report of 1 human pa-
tient with an IGF-1 gene deletion who
presented with severe IUGR.84,85 Simi-
larly, direct fetal infusion of IGF-1 pro-
motes fetal substrate uptake and inhibits
fetal catabolism.86 In contrast to the
postnatal situation, the dominant driver
of circulating fetal IGF-1 regulator is not
only the growth hormone (GH)87e89 but
also fetal insulin, which in turn is pre-
dominantly regulated by fetal glucose
availability.90,91 Thus, in this study,
inappropriate nutrition (inappropriate
glucose or insulin level), excessive
corticosteroid dose (especially Dex) that
might interfere with GH pulsation and
decrease total GH secretion and IGF-
1,92,93 and the absence of AF-derived
IGF-1 may combine to result in an
overall deficiency of IGF-1 levels and
become a factor in growth restriction.
Therefore, monitoring IGF-1 and IGF
binding proteins94 as an indicator of fetal
growth in the management of nutritionGLOSSARY
Artificial placenta: a gas exchange device
genators connected to the umbilical vessels
provided by the fetal heart.
Ex vivo uterine environment (EVE) therapy:
support to an extremely preterm infant by sim
Extremely preterm infants: infants born clo
weeks’ gestation.
Glucocorticoids: synthetic steroid hormone
through glucocorticoid receptor activation.
mature the preterm lung in anticipation of pre
Lipopolysaccharides: large lipid and polysacc
Gram-negative bacteria. Lipopolysaccharides
can be used to simulate intrauterine inflammand glucocorticoid use or replenishing
IGF-1 may improve outcomes in this
experimental system.
Brain injury
Gross anatomic observations and
assessment of H&Eestained brain sec-
tions identified the presence of patho-
logic lesions in 3 of the LPS control
group animals and 3 of 8 EVE group
animals (EVE 3, 4, and 8).
There was no evidence of hemorrhage
in any of the 6 LPS control and 8 EVE
group animals or of WMI in the
remaining 3 control and 6 EVE animals
in gross anatomic and H&Eestained
histopathologic analyses of coronal brain
sections (Table 5; Figure 5).
In addition, WMI has been associated
with prematurity especially below 32
weeks’ gestation, typically localized to
the periventricular white matter area in a
diffuse or focal pattern.95,96 In addition,
inflammation during fetal and neonatal
development alone has been linked to
brain injury.23,97,98 Similarly, extremely
preterm fetal sheep (GA of 91e93 days)
exposed to LPS reported WMI.41,99
Although the cause of this injury in this
study is unclear, it might derive from
hypoxic-ischemic change or proin-
flammatory cytokines mediating direct
effects.8,30,100e103
Conclusion
Extremely preterm sheep fetuses
compromised by a 48-hour antenatal
exposure to intrauterine inflammation
were maintained for a period of 120comprising 1 or more membranous oxy-
by indwelling catheters. Circuit pressure is
the use of an artificial placenta to provide life
ulating placental gas exchange.
se to the border of viability, that is, 21e24
s that exert pleiotropic signaling activity
Widely used in obstetrics to precociously
term delivery.
haride molecules found in the outer layer of
elicit a robust inflammatory response that
ation and generate chorioamnionitis.
NOVEMBER 2020 Americhours using an artificial placentaebased
life support platform. These studies have
identified 4 key issues for the future
development of this technology for
clinical application: (1) refractory hy-
potension, (2) growth restriction, (3)
brain injury, and (4) stabilizing circuit
performance to protect against WMI.
As such challenges are largely absent
in studies based on healthy sheep fetuses,
additional experiments of this nature are
essential for further development of this
technology. Although still preliminary,
these novel findings using extremely
preterm lambs compromised by expo-
sure to intrauterine inflammation do
demonstrate that, with significant addi-
tional development, there is potential
clinical utility for artificial placenta
technology to support extremely pre-
term infants. n
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